SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Market participants are actively discussing the broad economic implications of new tariff policies and trade tensions involving key U.S. allies, fueling a polarized debate on the administration's fiscal strategy. Sentiment remains heavily divided, with discussions frequently veering into heated political discourse regarding the current trade environment and potential impacts on the broader market.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing selling pressure as investors await updates on the launch schedule for upcoming satellites, despite ongoing community optimism regarding its direct-to-cell partnerships and long-term potential. Market sentiment remains cautious as the stock tracks broader volatility within the space sector, leading to active debate over whether current price levels present an accumulation opportunity or a signal of deeper execution risks.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors digest the launch of a new $1.59 billion USD cash pool, which the company intends to use for strategic flexibility, including future Bitcoin purchases and capital management. While some community members remain wary of ongoing share dilution, sentiment is heavily bullish as Bitcoin moves toward recent highs, fueling speculation about potential price appreciation and a short squeeze.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate whether recent volatility represents a significant accumulation phase or a continuation of a long-term downtrend. Community discourse remains deeply divided between those citing the project's payment infrastructure and compliance work as catalysts for a potential reversal and skeptics who express frustration over price performance and limited public updates.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio shares plunged following a surprise FDA clinical hold on the company's RGX-121 gene therapy for Hunter syndrome, citing asymptomatic spine MRI findings in study participants. Investors are debating whether this setback is a major blow or a temporary regulatory delay, while the company maintains its focus on upcoming catalysts in its Duchenne and retinal disease pipelines.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is seeing increased attention as the market balances strong corporate earnings and cooling inflation data against ongoing geopolitical tensions in the Middle East and concerns over surging Treasury yields. Investors are closely monitoring the impact of the Treasury's expanded bond buyback initiative as they weigh the potential for a soft landing against persistent macro-economic uncertainty.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is under intense market scrutiny ahead of its earnings report as investors weigh strong AI infrastructure demand against concerns over rising hardware costs and circular financing narratives. The community remains deeply divided, with some traders viewing the recent price slide as a strategic buying opportunity while others express skepticism regarding valuation and potential regulatory hurdles.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is currently trending due to intense volatility and algorithmic trading activity, with community discourse divided between investors betting on a long-term turnaround via autonomous driving and robotics, and traders aggressively shorting the stock amidst downward price pressure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is hovering near key resistance at $80,000, with investors closely watching treasury yield developments and upcoming economic policy announcements. The community remains divided between bullish sentiment fueled by potential safe-haven inflows and bearish skepticism regarding the sustainability of the current price action.

BTCT is a TRC20 token that is 100% backed by Bitcoin (BTC). The reserve addresses are published for anyone to audit.  Bitcoin uses peer-to-peer technology to operate with no central authority or banks; managing transactions and the issuing of bitcoins is carried out collectively by the network. Bitcoin is open-source; its design is public, nobody owns or controls Bitcoin and everyone can take part. Through many of its unique properties, Bitcoin allows exciting uses that could not be covered by any previous payment system.

Bitcoin TRC20

BTCT is drawing attention as the company approaches deployment readiness at its Georgia facility, fueling community discussions about its mining capacity and strategic expansion into AI infrastructure. Traders are closely monitoring the stock for potential momentum, though some are expressing caution regarding the impact of registered shares on future volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'

Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from...

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings 

Equity

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems. 


What's Going On With Neurocrine Biosciences Stock On Wednesday?

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.read more...

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

Neurocrine Biosciences Announces Publication of KINECT-PRO Findings Demonstrating INGREZZA (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences Announces Publication of KINECT-PRO Findings Demonstrating INGREZZA (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia Neurocrine Biosciences Announces Publication of KINECT-PRO Findings...

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Bullish Sentiment

Beat EPS and revenue 

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Nvidia ($NVDA) reports Q2 earnings Wednesday with Wall Street expecting roughly $91.7 billion in revenue — about 80% year-over-year growth — and EPS near $2.08. What do you expect in terms of revenue and EPS? Vote and explain your reasoning in the comments.

What do you expect from Nvidia ($NVDA) earnings on Wednesday?

Feed

News

Sentiment

Earnings

Fundamentals

Info